INmune Bio Inc., a late-stage biotech company focused on inflammation and immunology, will report its Q3 2026 financial results on November 5, 2026, at 4:30 PM ET. The company will host a conference call and webcast to discuss the quarter's outcomes and provide a corporate update. INmune Bio is advancing two late-stage product platforms, CORDStrom™ and XPro1595™, targeting regulatory filings and clinical milestones in the UK, EU, and US. Investors can access the live call online, with a replay available until December 21, 2026.
INmune Bio Inc. is reporting Q3 2026 financial results on November 5. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 29, 2026 19:12 WIB: Out of 150 priced US health stocks, 91 rose and 53 fell. Notable movers include IOVA at USD 10.99 with a 1-day change of -25.79% and 100% sell order activity, MESO at USD 15.83 up 18.22%, and HLN at USD 8.62 down 13.80%.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
